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Summary Background MET is a tyrosine kinase receptor
involved in the regulation of cell proliferation and migration.
Reported here are the phase I dose-escalation results for
LY2875358, a monoclonal antibody against MET, in
Japanese patients with advanced malignancies. Methods The
study comprised a 3 + 3 dose-escalation part for LY2875358
monotherapy in patients with advanced malignancies (Part A)
followed by an assessment of LY2875358 in combination
with erlotinib or gefitinib in patients with non-small cell lung
cancer (Part B). LY2875358 was administered once every
2 weeks. The primary objective was to evaluate the safety
and tolerability of LY2875358; secondary objectives included
evaluation of pharmacokinetics, pharmacodynamics, and an-
titumor activity. Results Eleven patients received LY2875358
monotherapy at 3 dose levels (700 mg,N = 3; 1400mg,N = 3;
2000 mg, N = 5) and 6 patients received LY2875358 2000 mg
in combination with erlotinib (N = 3) or gefitinib (N = 3). No
dose-limiting toxicities or serious adverse events related to
LY2875358 were observed. The most frequently reported
drug-related adverse events were hypoalbuminemia (2 pa-
tients) in Part A and dermatitis acneiform (4 patients) in Part
B. LY2875358 area under the curve (AUC) and maximum
concentration (Cmax) increased with dose over the dose range
of 700 mg to 2000 mg. A best response of stable disease was
achieved by 2/11 patients in Part A and 4/6 patients in Part B
(disease control rate: 35 %). Conclusions LY2875358 at doses
up to 2000mg demonstrated a favorable safety and tolerability
profile as monotherapy or in combination with erlotinib or
gefitinib in Japanese patients with advanced malignancies.
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Introduction
The hepatocyte growth factor (HGF) receptor, also known
as MET, is a tyrosine kinase receptor that has been associ-
ated with tumor progression and metastasis [1–3]. Aberrant
activation of the HGF/MET signaling pathway promotes
tumor cell growth, survival, angiogenesis, invasion, and
metastasis [1–3]. Many tumor types, including gastric, co-
lorectal, renal, breast, pancreatic, lung, thyroid, and hepa-
tocellular carcinoma, have aberrant activation of the HGF/
MET signaling pathway [1, 4–8]. Activation of this path-
way can occur by several mechanisms, including ligand-
dependent activation by HGF and ligand-independent, con-
stitutive activation of MET through gene amplification or
genetic mutations [3, 4, 9]. Elevated HGF expression and c-
MET amplification have been linked with acquired resis-
tance to epidermal growth factor receptor tyrosine kinase
inhibitors (EGFRTKIs) in patients with non-small cell lung
cancer (NSCLC) [10–13]. As the HGF/MET signaling
pathway plays a role in several key processes underlying
tumor progression, targeting this pathway is considered a
promising therapeutic strategy for the treatment of patients
with MET-expressing cancers, including those with
NSCLC who have acquired resistance to EGFR TKIs.
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LY2875358 is a humanized, bivalent, monoclonal, immu-
noglobulin G4 (IgG4) antibody against MET [14]. It prevents
ligand-dependent and ligand-independent activation of the
MET/HGF pathway; by binding to MET, LY2875358 blocks
the binding of HGF to METand thereby inhibits HGF ligand-
dependent induction of MET phosphorylation [14]. In addi-
tion, binding of LY2875358 to MET results in internalization
and degradation of MET, leading to suppression of ligand-
independent cell proliferation and tumor growth in preclinical
models where MET is constitutively activated [14]. These
characteristics suggest that LY2875358 is active against tu-
mors whether they are driven by elevated HGF expression
or constitutive MET activation. The first human dose study
of LY2875358 showed that administration as monotherapy
(dose range: 20 mg to 2000 mg) or in combination with erlo-
tinib (dose range: 700 mg to 2000 mg) was well tolerated in
patients with advanced solid tumors [15]. No dose-limiting
toxicities (DLTs), serious adverse events (SAEs), or ≥Grade
3 adverse events (AEs) possibly related to LY2875358 were
observed for LY2875358 monotherapy or LY2875358 plus
erlotinib in this mainly Caucasian patient population. The rec-
ommended phase II dose (RPTD) range of LY2875358 was
determined to be 700 mg to 2000 mg intravenously every
2 weeks for both monotherapy and combination therapy with
erlotinib.
The aim of this phase I study was to investigate the safety
of LY2875358 in Japanese patients. LY2875358 was admin-
istered as monotherapy in patients with advanced solid tumors
(Part A) or in combination with erlotinib or gefitinib in pa-
tients with advanced NSCLC (Part B). The primary objective
of the study was to assess the safety and tolerability of
LY2875358 at doses up to and including the RPTD range
from the first human dose study (Study JTBA) [15].
Secondary objectives included the assessment of toxicity,
pharmacokinetics, antitumor activity, and biomarker analysis.
Materials and methods
Study design
This study (Study JTBD) was a phase I, single-center, open-
label, nonrandomized, dose-escalation study of LY2875358 in
Japanese patients with advanced and/or metastatic malignan-
cies. The study consisted of two parts: a dose-escalation part
for LY2875358 monotherapy (Part A) followed by a cohort-
expansion part for LY287538 in combination with erlotinib
(Part B1) or gefitinib (Part B2). Dose escalations of
LY2875358 were performed following a standard 3 + 3 de-
sign. The study protocol was approved by the site’s ethics
review board and conducted in accordance with the
Declaration of Helsinki and GoodClinical Practice guidelines.
All patients provided written informed consent before
undergoing any study procedure. Patients who continued
study treatment after the first cycle of treatment signed a sec-
ond informed consent form before starting the second cycle of
treatment. The study was registered at www.clinicaltrials.gov
(NCT01602289).
Study population
Patients with histological or cytological evidence of ad-
vanced and/or metastatic malignancies who were consid-
ered an appropriate candidate for experimental therapy after
use of standard therapies were eligible for LY2875358
monotherapy (Part A). For the LY2875358 combination
cohorts (Part B), patients were eligible if they had histolog-
ical or cytological evidence of Stage IV NSCLC [16] (with
activating EGFR mutations for Part B2), had no other ef-
fective therapeutic option, and were suitable for erlotinib
(Part B1) or gefitinib (Part B2) therapy per the Japanese
package insert [17, 18]. Previous EGFR TKI treatment
was permitted.
Additional inclusion criteria for the study included:
age ≥ 20 years; measurable or unmeasurable disease by
Response Evaluation Criteria in Solid Tumors (RECIST) ver-
sion 1.1 [19]; Eastern Cooperative Oncology Group (ECOG)
performance status (PS) of ≤2; and adequate organ function.
Exclusion criteria included: symptomatic central nervous sys-
tem malignancy or metastasis (Part A); brain metastases that
were symptomatic or required ongoing treatment with steroids
or radiation therapy (Part B); active infection, including hu-
man immunodeficiency virus and hepatitis A, B, and C; pre-
vious treatment with any MET targeting agent; receiving war-
farin therapy (Part B); concomitant treatment with cytochrome
P450 3A4 modulators (no treatment with a modulator within
14 days of Cycle 1, Day 1; Part B); evidence of clinically
active interstitial lung disease or pre-existing interstitial lung
disease risk as demonstrated by computed tomography (Part
B); and any disease of acute lung injury, idiopathic pulmonary
fibrosis, pneumonitis, or pneumoconiosis (Part B).
Study treatments
Patients in the dose-escalation part (Part A) were enrolled
sequentially into LY2875358 dose cohorts of 700 mg,
1400 mg, and 2000 mg using a flat dosing scheme. Patients
were administered LY2875358 intravenously over approxi-
mately 90 min (700 mg cohort) or 150 min (1400 mg and
2000 mg cohorts) on Day 1 and Day 15 of a 28-day cycle,
until any discontinuation criterion was met.
In Part B, patients with Stage IV NSCLC were adminis-
tered LY2875358 2000 mg, using the same schedule and
method in Part A, in combination with erlotinib administered
orally as a once-daily dose of 150 mg (Part B1) or gefitinib
administered orally as a once-daily dose of 250 mg (Part B2).
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Dose-escalation method
Dose escalation of LY2875358 in Part A occurred sequentially
over the doses of 700 mg, 1400 mg, and 2000 mg until the
criteria for reaching the maximum tolerated dose (MTD) were
met or the highest planned dose cohort was completed. The
MTD was defined as the highest tested dose that had <33 %
probability of causing a DLT. A DLT was defined as an AE
during the DLTevaluation period (the first cycle: 28 days) that
was possibly related to the study drug (LY2875358 alone or in
combination with erlotinib/gefitinib) and fulfilled one of the
following criteria using the National Cancer Institute (NCI)
Common Terminology Criteria for Adverse Events
(CTCAE) version 4.02: ≥Grade 3 nonhematological toxicity;
Grade 4 neutropenia of duration >7 days; febrile neutropenia;
or Grade 3 thrombocytopenia with ≥Grade 2 bleeding or
Grade 4 thrombocytopenia with or without bleeding, regard-
less of duration.
Dose adjustments and delays
Dose adjustments of LY2875358 were not permitted during
the study. Before the start of each administration of
LY2875358, hematological toxicities (except anemia) and
nonhematological toxicities (except alopecia, fatigue, skin
rash, nausea, vomiting, or diarrhea that could be controlled
with treatment) possibly related to LY2875358 had to resolve
to ≤Grade 1 or baseline. The start of each administration of
LY2875358 could be delayed for up to 2 weeks to allow suf-
ficient time for recovery.
The erlotinib dose could be reduced for toxicities attribut-
able to erlotinib at the discretion of the investigator and ac-
cording to the Japanese package insert [17]. For gefitinib,
poorly tolerated diarrhea, treatment-related AEs of the skin,
or any other AE that the investigator believed was attributable
to gefitinib could be managed by dosing interruption (up to
14 days), followed by reinstatement of the 250 mg daily dose
at the discretion of the investigator and according to the
Japanese package insert [18].
Clinical assessments
Adverse events were graded using the NCI CTCAE version
4.02. Tumor response was assessed by RECIST version 1.1
[19] every other cycle after Cycle 2 or as clinically indicated.
Responses required confirmation by the same tumor imaging
method within 4 weeks of the initial observation of an objec-
tive response. The objective response rate (ORR) was defined
as the percentage of patients who experienced a complete
response (CR) or partial response (PR). The disease control
rate (DCR) was defined as the percentage of patients who
experienced a CR, PR, or stable disease (SD). Progression-
free survival (PFS) was measured from the date of the first
dose of study drug to the first date of objective progression of
disease or the date of death from any cause, whichever oc-
curred first.
Dose intensity
Relative dose intensity was the actual dose intensity (in mg/
week) expressed as a percentage of the planned weekly dose.
Pharmacokinetics
Blood samples were collected for pharmacokinetic analysis
during Cycle 1 as follows: before the infusion on Day 1,
mid-infusion, at the end of the infusion, 2, 4, 6, 8, and 24 h
(Day 2) after the end of the infusion, Day 4–6 at any time, Day
8, before the infusion on Day 15, at the end of the infusion, 2,
4, and 6 h after the end of the infusion, and Day 22. Blood
samples were collected for pharmacokinetic analysis during
Cycle 2 as follows: before the infusion on Day 1, mid-infu-
sion, at the end of the infusion, 2 and 4 h after the end of the
infusion, Day 8, before the infusion on Day 15, and at the end
of the infusion. The pharmacokinetic parameters for
LY2875358, erlotinib, and gefitinib were computed by stan-
dard noncompartmental methods using Phoenix WinNonlin
6.3 software (Certara USA, Inc., Princeton, NJ, USA).
Biomarker analysis
Immunohistochemical staining using the anti-MET antibody
A2H2-3 [20] was conducted for optionally available archival
tumor samples. A composite scoring system was devised to
determine the status of MET by immunohistochemistry.
Tumor samples with ≥50 % of cells stained 2+ or 3+ for
MET expression were considered MET diagnostic positive.
The H-score was calculated as described previously [21] as
the sum of 1 × (% of 1+ cells) + 2 × (% of 2+ cells) + 3 × (% of
3+ cells). Fluorescence in situ hybridization for the c-MET
gene was conducted to assess amplification in tumor samples.
The c-MET gene was considered to be amplified if the ratio of
the average copy number per cell of c-MET to the average
copy number per cell of the control chromosome 7 centromere
(CEP7) was ≥2. Serumwas collected pre-dose and throughout
the study and assessed for the circulating extracellular domain
(ECD) of MET by a validated enzyme-linked immunosorbent
assay.
Statistical analysis
The sample size was determined by the incidence of DLTs (up
to 6 patients per cohort, up to 30 patients in total). All patients
who received at least 1 dose of any study drug were evaluated
for safety, toxicity, and antitumor activity (full analysis set).
All patients who met the DLTcriteria at a particular dose level
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were evaluated for DLTs (DLT evaluation set). Descriptive
statistics were used to summarize safety and antitumor activ-




A total of 17 patients were enrolled in Study JTBD and re-
ceived at least 1 dose of LY2875358. Eleven patients were
enrolled in the LY2875358 monotherapy cohorts and received
700 mg (N = 3), 1400 mg (N = 3), or 2000 mg (N = 5)
LY2875358. Two patients in the 2000 mg monotherapy co-
hort were not evaluable for DLTs and were replaced (1 patient
discontinued study treatment after the first dose of study drug
because of an AE [hypoalbuminemia] not related to study
drug; 1 patient discontinued study treatment after the first dose
of study drug because of progressive disease [PD]). After
completion of Part A, a total of 6 patients were enrolled in
Part B to receive LY2875358 in combination with erlotinib
(Part B1; N = 3) or gefitinib (Part B2; N = 3). All patients
enrolled in the study were included in the safety and pharma-
cokinetic analyses.
Demographic and baseline clinical characteristics
All patients in this study had Stage IV solid tumors and had
received prior systemic therapy (Table 1). Patients enrolled in
Part A had a diagnosis of pancreatic adenocarcinoma, esoph-
ageal carcinoma (n = 2 for both), gastric adenocarcinoma,
biliary tract carcinoma, gall bladder carcinoma, neuroendo-
crine carcinoma, rectal carcinoma, thymic carcinoma, or gas-
trointestinal stromal tumors (n = 1 for all). All 6 patients in
Part B had a diagnosis of lung adenocarcinoma and had re-
ceived treatment with at least one first-generation EGFR TKI
before enrolling in the study. The baseline patient and disease
characteristics are summarized in Table 1.
Safety and tolerability
LY2875358 treatment was well tolerated, both when admin-
istered as monotherapy and when administered in combina-
tion with erlotinib or gefitinib. No DLTs were observed in any
patient enrolled in this study.
Six of 11 patients (54.5 %) in Part A reported at least 1 AE
possibly related to study drug (Table 2). The most frequently
reported AE considered possibly related to LY2875358 was
hypoalbuminemia, which was reported by 2 patients (1 patient
each in the 700 mg and 2000 mg cohorts). Three patients
reported 7 Grade ≥ 3 AEs; of these, the Grade 3 anemia re-
ported by 1 patient in the 700 mg cohort was considered
possibly related to LY2875358. This patient (who had Grade
1 anemia at baseline) reported Grade 2 anemia on Day 36 of
Cycle 1, which had developed to Grade 3 at the time of treat-
ment discontinuation. A total of 3 SAEs in 2 patients were
reported in Part A, none of which were considered possibly
related to LY2875358. This included 1 patient in the 1400 mg
cohort with Grade 4 sepsis and Grade 3 fatigue, and 1 patient
in the 2000 mg cohort with Grade 4 depressed level of con-
sciousness. One patient in the 1400 mg cohort reported a
Grade 2 infusion-related reaction considered possibly related
to LY2875358.
All patients in Part B receiving LY2875358 treatment in
combination with erlotinib or gefitinib reported at least 1 AE
possibly related to study drugs (Table 2). The most frequently
reported AEs considered possibly drug related (LY2875358 or
erlotinib/gefitinib) included dermatitis acneiform (n = 4), hy-
poalbuminemia (n = 3), diarrhea (n = 3), fatigue (n = 3), and
paronychia (n = 3). One patient in Part B2 experienced pe-
ripheral edema considered possibly related to LY2875358.
Two patients in Part B reported ≥Grade 3 AEs, both of which
(Grade 3 fatigue, Grade 3 stomatitis) were possibly related to
LY2875358. One patient in Part B1 reported an SAE of Grade
3 metastases to the thoracic spine, which was not considered
related to study drug.
Progressive disease was the primary reason for discontinu-
ation from study treatment (9/11 patients [81.8 %] in Part A
and 3/6 patients [50.0 %] in Part B). Two patients
discontinued study treatment because of an AE possibly relat-
ed to LY2875358: 1 patient in the 700 mg cohort because of
Grade 2 hypoalbuminemia and 1 patient in the LY2875358
plus gefitinib cohort because of a Grade 2 decreased platelet
count. No AEs leading to death were reported in this study.
Pharmacokinetics
The pharmacokinetic parameters of LY2875358 when admin-
istered as monotherapy or in combination with erlotinib or
gefitinib are shown in Table 3. Following administration of
LY2875358 monotherapy on Day 1 of Cycle 1 in Part A, the
maximum concentration (Cmax) and area under the concentra-
tion time-curve (AUC) from 0 h to infinity (AUC(0-∞)) in-
creased with increasing dose of LY2875358, whereas clear-
ance was similar across doses (Table 3). The tmax (time at
which maximum concentration is reached) values for the pa-
tients in the 3 LY2875358 monotherapy cohorts ranged from
1.47 h to 10.53 h (Table 3). The mean plasma LY2875358
concentration-time profiles following administration of
LY2875358 on Day 1 of Cycle 1, Day 15 of Cycle 1, and
Day 1 of Cycle 2 for the 3 LY2875358 monotherapy cohorts
are shown in Fig. 1. The geometric mean accumulation ratio
of LY2875358 on Day 1 of Cycle 2 based on the AUC during
one dosing interval (AUC(0-τ)) was within the range of 1.5 to
2.0 for the 3 LY2875358monotherapy cohorts. The geometric
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Table 3 Summary of pharmacokinetic parameters following administration of LY2875358 on Day 1 of Cycle 1
Geometric mean (CV%)
Part A Part B
Parameter LY2875358
700 mg (n = 3)
LY2875358
1400 mg (n = 3)
LY2875358
2000 mg (n = 5)
Part B1
LY2875358
2000 mg + Erlotinib (n = 3)
Part B2
LY2875358
2000 mg + Gefitinib (n = 3)
Cmax, μg/mL 219 (17) 395 (20) 575 (26) 589 (21) 704 (34)
tmax
a, hr 1.50 (1.47–7.52) 6.50 (4.48–10.53) 6.53 (2.58–8.50) 6.48 (4.50–8.53) 8.38 (2.55–10.63)
t1/2
b, hr 198 (157–265) 290 (266–342) 318 (262–637) 204 (163–238) 194 (137–288)
AUC(0-tlast), μg•hr./mL 30,900 (15) 63,000 (22) 96,400 (24) 98,500 (27) 92,600 (36)
AUC(0-∞), μg•hr./mL 44,900 (28) 113,000 (15) 154,000 (35) 145,000 (35) 134,000 (56)
CL, L/h 0.0158 (28) 0.0125 (15) 0.0131 (36) 0.0139 (35) 0.0150 (56)
Vss, L 4.45 (4) 5.14 (27) 5.85 (33) 4.03 (20) 4.14 (17)
Abbreviations: AUC(0-tlast) area under the concentration-time curve from 0 h to the time of the last measurable concentration, AUC(0-∞) area under the
concentration-time curve from 0 h to infinity, CL clearance, Cmax maximum concentration, CV coefficient of variation, t1/2 half-life, tmax time at which
maximum concentration is reached, Vss volume of distribution at steady state
aMedian (range)
b Geometric mean (range)
Fig. 1 Semi-logarithmic plot of mean serum LY2875358 concentration-time profiles following intravenous infusion of LY2875358 700 mg, 1400 mg,
2000 mg, 2000 mg plus erlotinib 150 mg/day, or 2000 mg plus gefitinib 250 mg/day on a Day 1 of Cycle 1, b Day 15 of Cycle 1, and c Day 1 of Cycle 2
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mean trough concentration of LY2875358 on Day 1 of Cycle
2 was 87.1, 176, and 251 μg/mL in the 700 mg, 1400 mg, and
2000 mg dose cohorts, respectively.
The pharmacokinetics of LY2875358 were not obviously
affected by the administration of erlotinib or gefitinib in Part
B1 or B2, respectively (Table 3, Fig. 1). In particular, Cmax,
AUC(0-∞), and clearance were similar between the
LY2875358 2000 mg dose cohort and the LY2875358
2000 mg plus erlotinib and LY2875358 2000 mg plus gefitin-
ib cohorts (Table 3). The tmax values for the patients in the
LY2875358 2000 mg plus erlotinib and LY2875358 2000 mg
plus gefitinib cohorts ranged from 2.55 h to 10.63 h (Table 3).
The mean plasma LY2875358 concentration-time profiles of
LY2875358 2000 mg plus erlotinib and LY2875358 2000 mg
plus gefitinib were similar to that of LY2875358 2000 mg
monotherapy following administration of LY2875358 on
Day 1 of Cycle 1, Day 15 of Cycle 1, and Day 1 of Cycle 2
(Fig. 1). The geometric mean accumulation ratio of
LY2875358 when administered in combination with erlotinib
or gefitinib was within the range of 1.5 to 2.0, as observed
when LY2875358 was administered as monotherapy. The
geometric mean trough concentration of LY2875358 on Day
1 of Cycle 2 was 233 and 251 μg/mL in the LY2875358
2000 mg plus erlotinib and LY2875358 2000 mg plus gefitin-
ib cohorts, respectively.
Dose intensity of LY2875358, erlotinib, and gefitinib
In Part A, patients received 1 to 5 cycles of LY2875358 treat-
ment, with a mean relative dose intensity of LY2875358 of
100 %, 98.8 %, and 79.1 % in the 700 mg, 1400 mg, and
2000 mg cohorts, respectively. Interruption of an
LY2875358 infusion occurred in 1 patient in the 1400 mg
cohort because of a Grade 2 infusion-related reaction; the
interruption lasted approximately 3 h, with the patient com-
pleting the full dose after the interruption.
In Part B, patients received 2 to 6 cycles of treatment. The
mean relative dose intensity of LY2875358 and erlotinib in
Part B1 was 87.9 % and 99.4 %, respectively. Omission of an
erlotinib dose occurred for 1 patient because of an AE (fa-
tigue). The mean relative dose intensity of LY2875358 and
gefitinib in Part B2 was 89.8 % and 99.8 %, respectively.
Omission of a gefitinib dose occurred for 1 patient because
of an investigator decision. No patients had a dose reduction
for erlotinib or gefitinib.
Antitumor activity
No complete or partial responses were observed in this study.
In Part A, 2/11 patients had a best response of SD (Table 4),
for a DCR of 18.2 %. This included 1 patient with thymic
carcinoma who had PFS of 43+ days (censored value) and 1
patient with gall bladder carcinoma who had PFS of 139 days.
In Part B, 4/6 patients had a best response of SD (n = 2 in each
part, Table 4), for a DCR of 66.7 %, and PFS ranged from 50
to 174 days.
Biomarker analyses
MET expression status from archival tumor samples was
available for 6 patients, of whom 1 patient (700 mg cohort,
pancreatic adenocarcinoma) was MET diagnostic positive,
having 70 % of cells staining 2+ for MET expression
(Table 4). Amplification status of c-METwas evaluable for 5
patients, none of whom had amplification of the c-MET gene
(Table 4).
In each of the LY2875358 monotherapy dose cohorts and
in the LY2875358 plus erlotinib cohort, an increase in circu-
lating MET ECD levels was observed after initiation of
LY2875358 treatment, which plateaued after approximately
4 weeks (Fig. 2a). There did not appear to be a clear dose-
dependent relationship between LY2875358 dose and circu-
lating MET ECD levels in the LY2875358 monotherapy dose
cohorts or in the LY2875358 plus erlotinib cohort (Fig. 2b).
This pharmacodynamic biomarker analysis was not available
for the LY2875358 plus gefitinib cohort at the time of the data
cut-off.
Discussion
Here we report the findings from a phase I dose-escalation
study for the bivalent MET antibody LY2875358 when ad-
ministered as monotherapy or in combination with first-
generation EGFR TKIs in a Japanese patient population with
advanced and/or metastatic malignancies. Besides confirming
the safety and tolerability of LY2875358 monotherapy and in
combination with erlotinib, this is the first study to evaluate
the safety and tolerability of LY2875358 in combination with
gefitinib in patients with advanced NSCLC with activating
EGFR mutations. Although only a small number of patients
received the combination of LY2875358 and gefitinib, the
observed safety and tolerability profile appears to be similarly
favorable to the combination with erlotinib.
Adverse events possibly related to LY2875358 were ob-
served at a low frequency and were mostly graded mild or
moderate in severity in Japanese patients. In both the current
study and the previously conducted phase I study of
LY2875358, where 23 patients with advanced solid tumors
received LY2875358 monotherapy and 14 patients with ad-
vanced NSCLC received LY2875358 plus erlotinib [15], there
were no DLTs or SAEs possibly related to LY2875358 mono-
therapy or in combination with erlotinib at any of the
LY2875358 doses evaluated. Although no patients in the pre-
vious phase I study reported AEs of ≥Grade 3 possibly related
to LY2875358 monotherapy [15], 1 patient in the current
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study (in the 700 mg dose cohort) reported Grade 3 anemia
possibly related to LY2875358. There was no dose dependen-
cy in the incidence of any AEs possibly related to LY2875358
in the current study. The only possibly related AE reported in
more than 1 patient for LY2875358 monotherapy was hypo-
albuminemia, which has previously been reported as a class-
related effect for agents targeting MET/HGF [22–24]. For
patients receiving LY2875358 plus erlotinib, 2 patients in
the current study reported Grade 3 AEs (fatigue, stomatitis)
possibly related to LY2875358.
For the first time, the combination of LY2875358 and gefi-
tinib was studied in patients with advanced NSCLC. No DLTs,
SAEs, or AEs ≥ Grade 3 possibly related to LY2875358 were
observed in patients receiving LY2875358 plus gefitinib. The
overall safety profile of LY2875358 plus gefitinib appeared to
be similar to that observed for LY2875358 plus erlotinib, with
mild to moderate hypoalbuminemia, diarrhea, decreased
platelet count, dermatitis acneiform, fatigue, paronychia, de-
creased appetite, dry skin, and pruritus reported for both com-
binations. The safety profile and the high relative dose intensity
of LY2875358 monotherapy and in combination with erlotinib
or gefitinib observed in the current study foster the notion that
LY2875358 may be safely administered with first-generation
EGFR TKIs at doses up to 2000 mg every 2 weeks.
The AUC and Cmax for LY2875358 increased with dose
over the range of 700 mg to 2000 mg in this population of
Japanese patients with advanced malignancies and did not
appear to be affected by combination with erlotinib or gefitin-
ib. In addition, clearance of LY2875358 was similar in pa-
tients receiving LY2875358 2000 mg as monotherapy and in
those receiving the same dose of LY2875358 in combination
with erlotinib or gefitinib. In general, the tmax values observed
in this study (1.47 h to 10.63 h) occurred after the end of the
LY2875358 infusion (1.5 h for the 700 mg dose and 2.5 h for
Fig. 2 Serum MET ECD
concentration vs (a) time and (b)
serum LY2875358 concentration
for individual patients in the
LY2875358 700 mg, 1400 mg,
and 2000 mg cohorts and the
LY2875358 2000 mg plus
erlotinib cohort. Abbreviations:
ECD = extracellular domain
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the 1400 mg and 2000 mg doses), which is consistent with the
pharmacokinetics of LY2875358 observed in Caucasian pa-
tients in Study JTBA [25]. The doses of LY2875358 used in
this study were chosen to achieve exposures associated with
tumor growth inhibition in xenograft models. The geometric
mean trough concentrations of LY2875358 on Day 1 of Cycle
2, which ranged from 87.1 to 251 μg/mL in the 5 cohorts,
exceeded the 60 μg/mL threshold associated with ≥90 % tu-
mor growth inhibition in the MKN45 xenograft model [25].
Although it should be noted that assessment of antitumor
activity was not a primary objective of the study and the num-
ber of patients evaluated was small, the potential for clinical
activity was shown in individual patients. While the majority
of patients who received LY2875358 monotherapy
discontinued the study with PD, 1 patient with gall bladder
cancer in the 2000 mg LY2875358 monotherapy dose cohort
received 5 cycles of treatment and had a best response of SD.
For LY2875358 in combination with erlotinib or gefitinib, 4
of 6 patients with NSCLC had a best response of SD, includ-
ing 1 patient in the LY2875358 plus gefitinib group who re-
ceived 6 cycles of treatment. It should be noted that all 6
patients had been previously treated with at least 1 first-
generation EGFR TKI and progressed on this therapy before
enrolling in the study.
Circulating MET ECD has been proposed as a surrogate
measure of target engagement in studies of MET antibodies
[23, 26]. At the doses tested in the current study, MET ECD
levels increased from baseline, but there was not a strong dose-
dependent relationship between circulating MET ECD and
doses of LY2875358. This result is in line with previous reports,
including the MET ECD data from the phase I dose-escalation
study of onartuzumab, a humanized monovalent monoclonal
antibody against MET [23]. In that study, there was a dose-
dependent threshold (between 1 mg/kg and 4 mg/kg) for in-
creasing MET ECD levels after onartuzumab treatment, with
no further dose-dependent increase in MET ECD with
onartuzumab doses higher than 4 mg/kg.
A limitation of the current study is the limited number of
patient tumor samples available for assessment of MET ex-
pression and c-MET amplification, precluding any assessment
of correlation betweenMETexpression and antitumor activity
of LY2875358. It would be of value to investigate the possi-
bility of such a correlation in future studies of LY2875358,
which could inform future patient tailoring strategies to iden-
tify patients who might benefit most from LY2875358
treatment.
In conclusion, LY2875358 administered at doses up to
2000 mg every 2 weeks in this phase I study was associated
with a favorable safety profile with no DLTs, both when ad-
ministered as monotherapy and in combination with erlotinib
or gefitinib. The tolerability and pharmacokinetic/
pharmacodynamic data in Japanese patients with advanced
malignancies support the globally recommended phase II dose
range of 700mg to 2000mg for LY2875358monotherapy and
in combination with erlotinib. LY2875358 is currently being
studied in combination with erlotinib in ongoing phase II trials
of patients with NSCLC.
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